REVB Q4 2024 Earnings — Revelation Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

REVBRevelation Biosciences, Inc.

$2M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26,964-28.2% YoY

Gross Profit

$13,48250.0% margin

Operating Income

-$2M-6504.6% margin

Net Income

-$2M-6400.1% margin

EPS (Diluted)

$-4.98

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$72,566

Balance Sheet

Total Assets

$7M

Total Liabilities

$2M

Stockholders' Equity

$5M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26,964	$37,574	-28.2%
Gross Profit	$13,482	$18,787	-28.2%
Operating Income	-$2M	-$2M	+24.6%
Net Income	-$2M	-$2M	+21.7%